A research team from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has discovered that the two key pathological hallmarks of Alzheimer's—tau protein and beta-amyloid ...

InMed Pharmaceuticals Inc., a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that it has ...

The successful financings come amid a more than two-year stretch when the sector has struggled to attract fresh capital with ...

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

The class’ availability online through Zoom is a major feature. With how Parkinson’s can affect movement, and the ability to travel not always guaranteed, having access to pivotal information ...

Taking longer to reach the rapid eye movement (REM) stage of sleep could mean you are more likely to develop dementia.

A new study has found that taking longer to reach the rapid eye movement (REM) stage of sleep is linked to a greater risk of ...

Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found ...

Scientists have discovered a potential new drug that could help people with Alzheimer’s disease by improving memory and ...

Annovis Bio (NYSE: ANVS) , a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that ...